.jpg/2000px-Fred_Ramsdell,_2015_(cropped).jpg)
Recent from talks
Fred Ramsdell
Knowledge base stats:
Talk channels stats:
Members stats:
Fred Ramsdell
Frederick Jay Ramsdell (born December 4, 1960) is an American immunologist. As of 2025, he is an advisor at Sonoma Biotherapeutics, a biotechnology company co-founded by him.
In 2025, he was jointly awarded the Nobel Prize in Physiology or Medicine with Mary E. Brunkow and Shimon Sakaguchi for their work in peripheral tolerance.
Ramsdell was born on December 4, 1960, in Elmhurst, Illinois.
As he was too poor for a four-year UC education, Ramsdell attended Foothill College out of Homestead High School (California) and then transferred to University of California, San Diego. He received a Bachelor of Science degree with a major in biochemistry and cell biology from UCSD in 1983. In the same year, he enrolled at the University of California, Los Angeles, as a doctoral student, and studied microbiology and immunology under the mentorship of Sidney Golub, receiving his PhD in 1987.
After earning his PhD, Ramsdell served a fellowship at the National Institutes of Health. After that, he joined the biopharmaceutical company Immunex, where his research focus was T cell activation and tolerance, and gene discovery. In 1994, he joined the Bothell, Washington-based biotechnology company Darwin Molecular (along with Mary E. Brunkow), where he established an immunology program. Darwin Molecular was acquired by Chiroscience in 1996. Three years later, Chiroscience merged with Celltech (briefly under the name Celltech Chiroscience). In 2004, Ramsdell and Brunkow left the company.
He joined ZymoGenetics in 2004 where he led research teams focusing on novel proteins with potential regulatory activity in lymphoid cells. In 2008, he started working at Novo Nordisk where he helped establish the firm's Inflammation Research Center in Seattle and became leader of the immunobiology group.
Later, he served as vice president at aTyr Pharma in San Diego, before joining the Parker Institute for Cancer Immunotherapy in San Francisco, where he was chief scientific officer.
In 2019, he co-founded the San Francisco-based Sonoma Biotherapeutics with Jeffrey Bluestone, Qizhi Tang and Alexander Rudensky, where he held the role of chief scientific officer. As of 2025, he is the chair of the company's scientific advisory board.
Hub AI
Fred Ramsdell AI simulator
(@Fred Ramsdell_simulator)
Fred Ramsdell
Frederick Jay Ramsdell (born December 4, 1960) is an American immunologist. As of 2025, he is an advisor at Sonoma Biotherapeutics, a biotechnology company co-founded by him.
In 2025, he was jointly awarded the Nobel Prize in Physiology or Medicine with Mary E. Brunkow and Shimon Sakaguchi for their work in peripheral tolerance.
Ramsdell was born on December 4, 1960, in Elmhurst, Illinois.
As he was too poor for a four-year UC education, Ramsdell attended Foothill College out of Homestead High School (California) and then transferred to University of California, San Diego. He received a Bachelor of Science degree with a major in biochemistry and cell biology from UCSD in 1983. In the same year, he enrolled at the University of California, Los Angeles, as a doctoral student, and studied microbiology and immunology under the mentorship of Sidney Golub, receiving his PhD in 1987.
After earning his PhD, Ramsdell served a fellowship at the National Institutes of Health. After that, he joined the biopharmaceutical company Immunex, where his research focus was T cell activation and tolerance, and gene discovery. In 1994, he joined the Bothell, Washington-based biotechnology company Darwin Molecular (along with Mary E. Brunkow), where he established an immunology program. Darwin Molecular was acquired by Chiroscience in 1996. Three years later, Chiroscience merged with Celltech (briefly under the name Celltech Chiroscience). In 2004, Ramsdell and Brunkow left the company.
He joined ZymoGenetics in 2004 where he led research teams focusing on novel proteins with potential regulatory activity in lymphoid cells. In 2008, he started working at Novo Nordisk where he helped establish the firm's Inflammation Research Center in Seattle and became leader of the immunobiology group.
Later, he served as vice president at aTyr Pharma in San Diego, before joining the Parker Institute for Cancer Immunotherapy in San Francisco, where he was chief scientific officer.
In 2019, he co-founded the San Francisco-based Sonoma Biotherapeutics with Jeffrey Bluestone, Qizhi Tang and Alexander Rudensky, where he held the role of chief scientific officer. As of 2025, he is the chair of the company's scientific advisory board.
Recent media